EUR 0.13
(-0.94%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 4.82 Million EUR | -86.11% |
2022 | 34.71 Million EUR | -36.76% |
2021 | 54.88 Million EUR | -15.66% |
2020 | 65.07 Million EUR | -9.99% |
2019 | 72.3 Million EUR | -31.48% |
2018 | 105.51 Million EUR | 58.07% |
2017 | 66.75 Million EUR | 32.7% |
2016 | 50.3 Million EUR | 7.38% |
2015 | 46.84 Million EUR | 238.84% |
2014 | 13.82 Million EUR | 12.72% |
2013 | 12.26 Million EUR | 49.9% |
2012 | 8.18 Million EUR | -19.58% |
2011 | 10.17 Million EUR | -19.86% |
2010 | 12.69 Million EUR | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 Q2 | 12.8 Million EUR | 0.0% |
2023 FY | - EUR | -100.0% |
2023 Q4 | 4.82 Million EUR | 0.0% |
2022 Q2 | 39.02 Million EUR | 0.0% |
2022 Q4 | 34.71 Million EUR | 0.0% |
2022 FY | 34.71 Million EUR | -36.76% |
2021 FY | 54.88 Million EUR | -15.66% |
2021 Q4 | 54.88 Million EUR | 0.0% |
2021 Q2 | 75.38 Million EUR | 0.0% |
2020 Q4 | 65.07 Million EUR | 0.0% |
2020 FY | 65.07 Million EUR | -9.99% |
2020 Q2 | 75.16 Million EUR | 0.0% |
2019 Q2 | 91.08 Million EUR | 0.0% |
2019 Q4 | 72.3 Million EUR | 0.0% |
2019 FY | 72.3 Million EUR | -31.48% |
2018 Q2 | 112.66 Million EUR | 0.0% |
2018 FY | 105.51 Million EUR | 58.07% |
2018 Q4 | 105.51 Million EUR | 0.0% |
2017 Q2 | 38.01 Million EUR | 0.0% |
2017 FY | 66.75 Million EUR | 32.7% |
2017 Q4 | 66.75 Million EUR | 0.0% |
2016 Q2 | 37.34 Million EUR | 0.0% |
2016 FY | 50.3 Million EUR | 7.38% |
2016 Q4 | 50.3 Million EUR | 0.0% |
2015 FY | 46.84 Million EUR | 238.84% |
2015 Q2 | 33.45 Million EUR | 0.0% |
2015 Q4 | 46.84 Million EUR | 0.0% |
2014 Q2 | 8.52 Million EUR | 0.0% |
2014 Q4 | 13.82 Million EUR | 0.0% |
2014 FY | 13.82 Million EUR | 12.72% |
2013 Q4 | 12.26 Million EUR | 0.0% |
2013 FY | 12.26 Million EUR | 49.9% |
2012 FY | 8.18 Million EUR | -19.58% |
2011 FY | 10.17 Million EUR | -19.86% |
2010 FY | 12.69 Million EUR | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
ABIONYX Pharma SA | 14.71 Million EUR | 67.213% |
ABIVAX Société Anonyme | 327.06 Million EUR | 98.525% |
Adocia SA | 24.95 Million EUR | 80.674% |
Aelis Farma SA | 26.28 Million EUR | 81.648% |
Biophytis S.A. | 11.93 Million EUR | 59.593% |
Advicenne S.A. | 12.4 Million EUR | 61.127% |
genOway Société anonyme | 31.84 Million EUR | 84.854% |
IntegraGen SA | 8 Million EUR | 39.715% |
Medesis Pharma S.A. | 1.92 Million EUR | -150.372% |
Neovacs S.A. | 47.53 Million EUR | 89.853% |
NFL Biosciences SA | 3.97 Million EUR | -21.467% |
Plant Advanced Technologies SA | 14.91 Million EUR | 67.659% |
Quantum Genomics Société Anonyme | 3.74 Million EUR | -28.724% |
Sensorion SA | 46.49 Million EUR | 89.627% |
Theranexus Société Anonyme | 7.23 Million EUR | 33.363% |
TME Pharma N.V. | 2.49 Million EUR | -93.617% |
Valbiotis SA | 33.24 Million EUR | 85.494% |
TheraVet SA | 7.53 Million EUR | 35.985% |
Valerio Therapeutics Société anonyme | 35.27 Million EUR | 86.327% |
argenx SE | 4.11 Billion EUR | 99.883% |
BioSenic S.A. | 9.55 Million EUR | 49.545% |
Celyad Oncology SA | 16.28 Million EUR | 70.378% |
DBV Technologies S.A. | 165.65 Million USD | 97.088% |
Galapagos NV | 4.35 Billion EUR | 99.889% |
Genfit S.A. | 173.87 Million EUR | 97.226% |
GeNeuro SA | 6.31 Million EUR | 23.601% |
Hyloris Pharmaceuticals SA | 47.68 Million EUR | 89.885% |
Innate Pharma S.A. | 184.19 Million EUR | 97.382% |
Inventiva S.A. | 69.13 Million EUR | 93.024% |
MaaT Pharma SA | 42.93 Million EUR | 88.766% |
MedinCell S.A. | 36.94 Million EUR | 86.947% |
Nanobiotix S.A. | 93.89 Million EUR | 94.864% |
Onward Medical N.V. | 43.62 Million EUR | 88.945% |
Oryzon Genomics S.A. | 106.9 Million EUR | 95.488% |
OSE Immunotherapeutics SA | 81.9 Million EUR | 94.111% |
Oxurion NV | 6.55 Million EUR | 26.366% |
Pharming Group N.V. | 426.33 Million EUR | 98.869% |
GenSight Biologics S.A. | 9.08 Million EUR | 46.924% |
Transgene SA | 45.21 Million EUR | 89.334% |
Financière de Tubize SA | 1.92 Billion EUR | 99.749% |
UCB SA | 15.53 Billion EUR | 99.969% |
Valneva SE | 469.39 Million EUR | 98.972% |
Vivoryon Therapeutics N.V. | 30.82 Million EUR | 84.356% |